Previous 10 |
Melinta Therapeutics (NASDAQ: MLNT ) announces the closing and receipt of the initial $75M disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019. More news on: Melinta Therapeutics, Healthcare stocks news, Stocks on...
– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 – MORRISTOWN, N.J....
NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a o...
Solid Biosciences (NASDAQ: SLDB ) -72% on disappointing DMD gene therapy data. More news on: Solid Biosciences, Inc., USA Technologies, Inc., Avadel Pharmaceuticals plc, Stocks on the move, Read more ...
Amyris (NASDAQ: AMRS ) +41% on $255M cannabinoid deal . More news on: Amyris, Inc., Melinta Therapeutics, Moleculin Biotech, Inc., Stocks on the move, Read more ...
Melinta Therapeutics (NASDAQ: MLNT ) provides an update on its strategic repositioning initiatives, cost savings outlook and new appointments. More news on: Melinta Therapeutics, Healthcare stocks news, Read more ...
~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) ...
Melinta Therapeutics (NASDAQ: MLNT ) initiated with Buy rating and $15 (249% upside) price target at Jefferies. Shares up 12% premarket. More news on: Melinta Therapeutics, Tabula Rasa HealthCare, Endo International plc, Healthcare stocks news, Stocks on the move, , Read mo...
NEW HAVEN, Conn., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company will be attending and hosting meet...
News, Short Squeeze, Breakout and More Instantly...
Melinta Therapeutics Inc - Ordinary Shares Company Name:
MLNT Stock Symbol:
NASDAQ Market:
MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purch...
Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotic...
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MO...